Igenica to Present New Data at the World ADC Summit
BURLINGAME, Calif.--(BUSINESS WIRE)--Igenica, Inc., a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it will present insights into its proteomic target discovery platform and ADC technology during a plenary session of the World ADC meeting, being held February 17-20 in Frankfurt, Germany.
The schedule for the presentation is as follows:
|Date & Time:||Tuesday, February 18, 2014, 4:30 p.m. CET|
|Session:||Approaches for Maximizing Therapeutic Index|
|Title:||Disease Relevant Targets for the Development of Next Generation ADCs|
|Presenter:||Thi-Sau Migone, Ph.D., Chief Scientific Officer of Igenica|
For more information about the conference, see the full program here.
About Igenica, Inc.
Igenica, Inc. is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. Igenica is the only biotherapeutic company that fully powers the ADC development spectrum from a patient-based approach to target and functional antibody discovery to the generation and manufacturing of homogeneous ADCs. Igenica’s integrated discovery engine has generated a robust pipeline of site-specific ADC candidates and functional antibodies to address critical needs of cancer patients. Led by a proven team of leaders with expertise in the development of therapeutic antibodies and ADCs, Igenica is funded by a premier group of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. For more information, please visit www.igenica.com.